Evidence map›Paper›PMID 33132329›Full record

ReviewInternal medicine (Tokyo, Japan)2021

Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review.

Yuki Yoshimatsu, Noriyuki Ebi, Ryunosuke Ooi, Takuto Sueyasu, Saori Nishizawa, Miyuki Munechika, Kohei Yoshimine, Yuki Ko, Hiromi Ide, Kosuke Tsuruno and 1 more

Open access · diamondAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Internal medicine (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Receptor tyrosine kinase inhibitors in cancer.Cellular and molecular life sciences : CMLS · 2023
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yuki YoshimatsuDepartment of Respiratory Medicine, Iizuka Hospital, Japan.
Noriyuki EbiDepartment of Respiratory Medicine, Iizuka Hospital, Japan.
Ryunosuke OoiDepartment of Respiratory Medicine, Iizuka Hospital, Japan.
Takuto SueyasuDepartment of Respiratory Medicine, Iizuka Hospital, Japan.
Saori NishizawaDepartment of Respiratory Medicine, Iizuka Hospital, Japan.
Miyuki MunechikaDepartment of Respiratory Medicine, Iizuka Hospital, Japan.
Kohei YoshimineDepartment of Respiratory Medicine, Iizuka Hospital, Japan.
Yuki KoDepartment of Respiratory Medicine, Iizuka Hospital, Japan.
Hiromi IdeDepartment of Respiratory Medicine, Iizuka Hospital, Japan.
Kosuke TsurunoDepartment of Respiratory Medicine, Iizuka Hospital, Japan.
Kazunori TobinoDepartment of Respiratory Medicine, Iizuka Hospital, Japan.
Aso Iizuka Hospital · JPHyogo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung squamous cell carcinoma is said to be low. Thus far, only four cases of osimertinib in lung squamous cell carcinoma have been published. We experienced a case of EGFR mutant lung squamous cell carcinoma in which fifth-line treatment with osimertinib was effective after T790M EGFR mutation turned positive. Osimertinib was resumed after sixth-line chemotherapy was ineffective, showing efficacy again. Osimertinib may be a promising treatment option for EGFR mutant lung squamous cell carcinoma. This is the first report to show its effect in a case of rechallenge after intervening chemotherapy. It may therefore be important to evaluate EGFR in never-smoker lung squamous cell carcinoma patients.

Indexed as

Antineoplastic AgentsCarcinoma, Squamous CellLung NeoplasmsAcrylamidesAniline CompoundsErbB ReceptorsHumansIndolesLungMutationProtein Kinase InhibitorsPyrimidinesAcrylamidesAniline CompoundsAntineoplastic AgentsErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsPyrimidinesadenosquamousEGFRepidermal growth factor receptorrechallengeTKItyrosine kinase inhibitor

Identifiers

PMID33132329
PMCPMC8079920
OpenAlexW3097061826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.